SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 9, 2024-- Vistagen (Nasdaq: VTGN), a clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain

Mental Health America’s highest national certification enhances Vistagen’s ongoing efforts to promote mental health throughout the U.S. SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 27, 2024-- Vistagen (Nasdaq: VTGN), a clinical-stage neuroscience-focused biopharmaceutical company dedicated

Registration-directed fasedienol PALISADE Phase 3 program for the acute treatment of social anxiety disorder progressing on track PALISADE-3 Phase 3 trial recently initiated; PALISADE-4 Phase 3 trial initiation anticipated in 2H 2024 SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun.

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 7, 2024-- Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced it will host a

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 29, 2024-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that company

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 23, 2024-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that it will present

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 7, 2024-- Vistagen (Nasdaq: VTGN), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that company management will present and

PH15 nasal spray demonstrates statistically significant efficacy versus placebo and caffeine in a placebo-controlled Phase 2A pilot study in sleep-deprived participants PH15 was safe and well-tolerated with an adverse event profile similar to placebo SOUTH SAN FRANCISCO, Calif.

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 9, 2024-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that it will present

Key study underway in registration-directed PALISADE Phase 3 program for fasedienol in social anxiety disorder Social anxiety disorder affects over 25 million Americans SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 1, 2024-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical